Page last updated: 2024-11-13

7-hydroxywarfarin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

7-hydroxywarfarin: a warfarin metabolite [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID54682507
CHEMBL ID145880
CHEBI ID180534
SCHEMBL ID17132373
MeSH IDM0232543

Synonyms (33)

Synonym
7-hydroxywarfarin
CHEBI:180534
17834-03-6
4,7-dihydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-one
NCGC00165932-01
CHEMBL145880
2,7-dihydroxy-3-(3-oxo-1-phenyl-butyl)chromen-4-one
A812360
b92sfw09lj ,
unii-b92sfw09lj
4,7-dihydroxy-3-(3-oxo-1-phenylbutyl)-2h-1-benzopyran-2-one
2h-1-benzopyran-2-one, 4,7-dihydroxy-3-(3-oxo-1-phenylbutyl)-
63740-81-8
7-hydroxy warfarin
FT-0637612
coumarin, 3-(.alpha.-acetonylbenzyl)-4,7-dihydroxy-
BQSUFDMOXLLKQK-UHFFFAOYSA-N
3-(.alpha.-acetonylbenzyl)-4,7-dihydroxycoumarin
SCHEMBL17132373
AS-71155
7-hydroxy warfarin
(r)-7-hydroxy warfarin
4,7-dihydroxy-3-(3-oxo-1-phenylbutyl)-2h-chromen-2-one
DTXSID10939074
2,7-dihydroxy-3-(3-oxo-1-phenylbutyl)-4h-1-benzopyran-4-one
Q27274527
3-(alpha-acetonylbenzyl)-4,7-dihydroxycoumarin
AKOS037646845
STARBLD0009682
PD039346
2h-1-benzopyran-2-one, 4,7-dihydroxy-3-[3-oxo-1-(phenyl-d5)butyl]-
2h-1-benzopyran-2-one, 4,7-dihydroxy-3-[(1s)-3-oxo-1-phenylbutyl]-
2,7-dihydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-4-one

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The mean plasma concentrations and elimination half-life of (R)-warfarin of all the subjects were about 2-fold greater than those of (S)-warfarin."( The effect of CYP2C19 genotypes on the pharmacokinetics of warfarin enantiomers.
Sugawara, K; Sugimoto, K; Tateishi, T; Uno, T, 2008
)
0.35
" Pharmacokinetic parameters were analysed using non-compartmental methods."( Effects of etravirine on the pharmacokinetics and pharmacodynamics of warfarin in rats.
Abobo, CV; Hsiao, C; John, J; John, M; Liang, D; Wu, L, 2013
)
0.39

Compound-Compound Interactions

ExcerptReferenceRelevance
" These data suggest that fluconazole can be expected to interact with any drug whose clearance is dominated by P450s 2C9, 3A4, and other as yet undefined isoforms."( Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies.
Bauwens, JE; Black, DJ; Evans, JS; Gidal, BE; Kunze, KL; McDonnell, ND; Seaton, TL; Trager, WF; Wienkers, LC, 1996
)
0.29

Dosage Studied

ExcerptRelevanceReference
" Dosing with St John's wort or ginseng was continued for 7 days after administration of the warfarin dose."( Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
Ammit, AJ; Day, RO; Duke, CC; Jiang, X; Liauw, WS; McLachlan, AJ; Roufogalis, BD; Williams, KM, 2004
)
0.32
"The aim of this study was to determine whether folic acid supplementation increases the dosage requirement of the CYP2C9 substrate warfarin, and the formation clearance of the CYP2C9-mediated product, (S)-7-hydroxywarfarin."( Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of long-term administration in adults.
Adar, L; Bialer, O; Blotnick, S; Caraco, Y; Cascorbi, I; Muszkat, M; Ufer, M; Xie, HG, 2010
)
0.55
"Patients aged >or=18 years with folic acid deficiency who were receiving long-term treatment with a stable dosage of warfarin were studied prospectively, before and 30 to 60 days after the initiation of supplementation with folic acid."( Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of long-term administration in adults.
Adar, L; Bialer, O; Blotnick, S; Caraco, Y; Cascorbi, I; Muszkat, M; Ufer, M; Xie, HG, 2010
)
0.36
" Changes in warfarin dosage requirements and INR were nonsignificant."( Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of long-term administration in adults.
Adar, L; Bialer, O; Blotnick, S; Caraco, Y; Cascorbi, I; Muszkat, M; Ufer, M; Xie, HG, 2010
)
0.36
"The present study results provide, insights on the effect of CYP2C9 genetic polymorphisms on inter-individual variability in warfarin metabolism and emphasizes utility of phenotyping in a setting of genotype-guided dosing of warfarin in South Indian population."( Influence of CYP2C9 Polymorphisms on Plasma Concentration of Warfarin and 7-Hydroxy Warfarin in South Indian Patients.
Adithan, C; Chandran B V, S; Kumar, DK; Shewade, DG; Uppugunduri, CRS, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
hydroxycoumarinAny coumarin carrying at least one hydroxy substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID16345Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Substrate probes for the mechanism of aromatic hydroxylation catalyzed by cytochrome P-450: selectively deuterated analogues of warfarin.
AID16342Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Substrate probes for the mechanism of aromatic hydroxylation catalyzed by cytochrome P-450: selectively deuterated analogues of warfarin.
AID16340Amount of deuterium retained was reported after normal workup in rats1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Substrate probes for the mechanism of aromatic hydroxylation catalyzed by cytochrome P-450: selectively deuterated analogues of warfarin.
AID16341Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Substrate probes for the mechanism of aromatic hydroxylation catalyzed by cytochrome P-450: selectively deuterated analogues of warfarin.
AID16343Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Substrate probes for the mechanism of aromatic hydroxylation catalyzed by cytochrome P-450: selectively deuterated analogues of warfarin.
AID293981Inhibition of rat microsomal VKER2007Bioorganic & medicinal chemistry, Mar-15, Volume: 15, Issue:6
Synthesis and structure-activity relationships of novel warfarin derivatives.
AID16339Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Substrate probes for the mechanism of aromatic hydroxylation catalyzed by cytochrome P-450: selectively deuterated analogues of warfarin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (36)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (2.78)18.7374
1990's7 (19.44)18.2507
2000's11 (30.56)29.6817
2010's15 (41.67)24.3611
2020's2 (5.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.22 (24.57)
Research Supply Index3.71 (2.92)
Research Growth Index5.30 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (11.11%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other32 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]